Our Team

Each Partner brings extensive industry knowledge, unrivaled relationships and substantial deal experience, resulting in a team of the industry's most sought after advisors

E. Eric Tokat

E. Eric Tokat is a partner and a founding member of the Healthcare practice at Centerview Partners.  During his career, Mr. Tokat advised numerous clients on a broad range of strategic advisory assignments and transactions exceeding $350 billion in value across developed and emerging markets. 

Mr. Tokat’s recent life sciences transactions include:
2020: $2.75bn sale of VelosBio to Merck; $2.9bn sale of Eidos to BridgeBio; $650M sale of Biospecifics to Endo; Up to $1.75bn sale of exclusive option to acquire Pionyr Immunotherapeutics to Gilead; Merck’s spin off of Organon
  • 2021: $2.3bn sale of Trillium Therapeutics to Pfizer; Up to $2bn sale of Vividion Therapeutics to Bayer AG; $1.7bn sale of Constellation Pharmaceuticals to Morphosys AG; $1.9bn sale of Pandion Therapeutics to Merck; $4.6bn sale of Cantel Medical to Steris; $200M investment in Immunovant by Roivant; Sale of Lengo Therapeutics to Blueprint Medicines for up to $465M; Sale of Sanifit to Vifor Pharma for up to €375M; Pfizer’s spin out of select Autoimmune assets and creation of Priovant
  • 2020: $1bn sale of Prevail Therapeutics to Eli Lilly; $2.75bn sale of VelosBio to Merck; $2.9bn sale of Eidos to BridgeBio; $650M sale of Biospecifics to Endo; Up to $1.75bn sale of exclusive option to acquire Pionyr Immunotherapeutics to Gilead; Merck’s spin off of Organon
  • 2019: ArQule's $2.7bn sale to Merck; Synthorx's $2.5bn sale to Sanofi; Achillion's up to $1.2bn sale to Alexion; Ra Pharma's $2.5bn sale to UCB S.A., Exact Sciences’ $2.8bn acquisition of Genomic Health; Peloton Therapeutics’ up to $2.2bn sale to Merck; Spark Therapeutics’ $4.8bn sale to Roche; Ipsen’s up to $1.3bn acquisition of Clementia Pharmaceuticals
  • 2018: Merck’s €3.25bn acquisition of Antellia; Syntimmune’s up to $1.2bn sale to Alexion; Pfizer’s consumer JV with GSK; Pfizer’s spin out of CAR-T assets and creation of Allogene; Pfizer’s spin out of Neuroscience assets and creation of Cerevel Therapeutics; Synergy Pharmaceutical’s sale to Bausch Health
  • 2017: Kite Pharma’s $12bn sale to Gilead; Valeant’s $1bn sale of Dendreon to Sanpower Group; China Regenerative Medicine’s acquisition of Obagi Medical from Valeant
  • 2016: Pfizer’s $14bn acquisition of Medivation and $5bn acquisition of Anacor; Raptor’s $1bn sale to Horizon; Mylan’s $10bn acquisition of Meda
  • 2015: Salix’s $16bn sale to Valeant; Dyax’s $6bn sale to Shire; Achillion's up to $1bn WW HCV collaboration with and $225m equity investment by J&J; Dendreon’s sale to Valeant
  • 2014: Algeta’s $3bn sale to Bayer; Cadence Pharmaceuticals’ $1bn sale to Mallinckrodt; Mylan’s $5bn acquisition of Abbott’s Branded Generics business in an inversion transaction and $1bn acquisition of FamyCare; BioAlliance Pharma’s merger with Topotarget to form Onxeo
  • 2013: Trius Therapeutics’ up to $1bn sale to Cubist; Optimer Pharmaceuticals’ up to $1bn sale to Cubist; Phillip Morris’ joint venture with Mitsubishi Tanebe and subsequent joint acquisition of Medicago
  • 2012: Pfizer’s $12bn sale of its Nutrition Business to Nestlé
  • 2011: OSI’s $4bn sale to Astellas; Ventas’ $7bn acquisition of NHP
Mr. Tokat’s other healthcare transactions include: Pfizer’s $68bn acquisition of Wyeth; $33bn LBO of HCA; AstraZeneca's $15bn acquisition of MedImmune; Celgene’s $3bn acquisition of Pharmion; New River Pharmaceuticals’ $3bn sale to Shire; ICOS' $2bn sale to Eli Lilly; LifeCell's $2bn sale to Kinetic Concepts; Cougar Biotechnology's $1bn sale to J&J; Haemonetics' acquisition of Pall Corp.'s Blood Filtration Business;  Thirdwave Technologies' sale to Hologic; Virochem’s sale to Vertex; the LBO of Symbion; Intercell’s acquisition of Iomai; American Bioscience’s merger with American Pharmaceutical Partners.

Mr. Tokat serves on a number of not-for-profit boards, including: a trustee at the Brookings Institution, chair of the Audit Committee at the IRC (International Rescue Committee), and vice chair of the Board of the Columbia University's Mailman School of Public Health.  He is a member of the Council on Foreign Relations.

Mr. Tokat received his BA from Bogazici University and MIA from Columbia University.
Centerview Partners takes a “One Firm” approach to deliver unmatched intellectual capital and integrity to all of our clients. We have industry-leading expertise in:

Centerview is honored to partner with leading charitable organizations in active support of our charities:

  • Arts Connection
  • NY Cares
  • Bottomless Closet
Church & Dwight
Announced: Q4 2021
Value: $580 million
Status: Pending

Financial advisor to Church & Dwight on its acquisition of the TheraBreath brand
View All
New York

Centerview Partners LLC

31 West 52nd Street

22nd Floor

New York, New York 10019

(212) 380-2650 | Tel
(212) 380-2651 | Fax

Centerview Partners UK LLP

100 Pall Mall

3rd Floor

London SW1Y 5NQ

02074099700 | Tel
02074099704 | Fax

Centerview Partners France SCS

16 Avenue Matignon

4th Floor

Paris 75008

0180200620 | Tel
0180200621 | Fax
Palo Alto

Centerview Partners LLC

600 Ramona St.

Suite 300

Palo Alto, California 94301

(650) 822-5800 | Tel
(650) 822-5801 | Fax
San Francisco

Centerview Partners LLC

555 California Street

Suite 4300

San Francisco, California 94104

(415) 400-0900 | Tel
(415) 400-0901 | Fax


Centerview Partners LLC

Los Angeles

Centerview Partners LLC

Copyright © 2008 - 2021 Centerview Partners Holdings LP. All Rights Reserved. | Privacy and Other Notices

Centerview Partners LLC, member SIPC